Revenue growth masks 93.7% PAT collapse; legacy projects, Roha costs, geopolitical headwinds cripple margins

₹700.5 Cr revenue achieved, but PAT collapsed 93.7% YoY to ₹3.1 Cr (NPM 0.44%)

₹230 Cr revenue +21%, but EBIT fell 52% YoY to ₹22 Cr due to Roha startup costs (~6% margin drag) + geopolitical impact + FX headwinds

₹210 Cr revenue +14% YoY, but segment reported EBIT loss of ₹17 Cr (negative 8% margin) due to legacy projects

₹105 Cr revenue +14% YoY, EBIT ₹13 Cr, margin improved to 11.89% from <6% prior year. Only healthy segment.

₹112 Cr revenue +33% YoY, but still loss-making at ₹0.34 Cr loss (vs ₹0.45 Cr prior year). Marginal improvement only.

Prior FY26 call: 'clarity expected in H2'. This call: no FY27 margin target reaffirmed; Roha utilization acknowledged as softer; legacy project not closing in FY27. NPM 0.44% vs prior 4%+ implies severe near-term pressure.

Hyundai (₹400+ Cr, low-risk solution variant) + Oman concession (20-year recurring) announced post-quarter. Management emphasizes selectivity on higher-margin advanced solutions. However, Q1 treatment solutions EBIT = -₹17 Cr undermines near-term upside.

New disclosure: 50% capacity increase over next 2 years (Roha + pharma + additional de-bottlenecking). Prior call mentioned Roha but not quantified incremental target. This is transparency upgrade, not a changed commitment.

Prior call noted dynamic situation, hoped for clarity in H2. Q1 call: geopolitical situation still 'extremely uncertain, fluid, fluctuating.' Input costs softening (crude ₹100 → ₹80/barrel) but lag in pass-through. Management admits invoicing impact ongoing.

Prior call: plan to break even in FY26. This call: plan to break even in FY27 (one-year slip). Loss improved ₹45 lakh → ₹34 lakh YoY, but at ₹112 Cr revenue the loss margin is still ~0.3%. Target maintained but credibility eroding.

We continue to hold on. Four months gone, softer than expected. Not throwing in towel. By end of Q2 we'll be in better position to share, depending on progress this quarter.

Legacy projects still grinding. Significant work done but fair bit left. We're selective on projects, looking at high-tech advanced solutions. Will take time to improve mix profile.

FX gain in prior year ~3-4%. Input cost increases passed through with time lag. Expecting moderation if crude softens. Should claw back margin in current year.

We never said UP would be fully over in FY27. Funds constrained last year, now inflows started. Premature to close in this FY. Will spill to next FY. Apart from UP, at least one other large legacy project plus smaller ones. Significant portion of work complete.

Contract just picked up. Kickoff meetings happening. Supply to EPC, not end customer. FOB Mumbai liability. Not anticipating delay. However, if crisis continues geopolitically, cause for worry.

Reporting isn't one-to-one. Significant profitability sits in products and chemicals segments. True segment profitability much higher and comparable. Lifecycle P&L alone doesn't reflect true segment result.

Geopolitical situation remains 'extremely uncertain, fluid, fluctuating'. Management declines to quantify.

Roha Phase I already delivering; Phase II + de-bottlenecking to follow. Current base ~₹900 Cr, so target ~₹1,350 Cr+ by FY28-29. Asset turnover target <2x on capex.

Management says 'cautiously confident we have clear path' but provides no specific margin target for FY27 or FY28. Prior Q21-22 achieved 11-12% EBIT on treatment solutions; now at -8.1%.

Full-year Roha ramp will reduce startup drag. Input cost normalization expected if crude stabilizes. Time lag in passing costs should resolve.

Currently ₹112 Cr revenue at loss. Requires either revenue acceleration or cost discipline. 33% growth trajectory suggests scale could be reached; prior year overrun suggests execution risk.

Likely understated. Roha expansion Phase II, pharma resins build-out (₹50+ Cr), membranes plant (₹100+ Cr estimated) are all ongoing and material. Prior guidance appears obsolete.

Treatment solutions -₹17 Cr EBIT on ₹210 Cr revenue directly attributable to U.P. and other large legacy projects. U.P. project unexecuted portion ~11% of total order backlog; management concedes 'significant part done, fair bit still left'; expects spill into FY28.

Roha plant in stabilization phase; targeting 25% utilization in FY27 but management acknowledges 'softer than expected' performance in first 4 months. Startup costs currently dragging specialty chemicals margin by ~6%. Full ramp and profitability breakeven dependent on global resin demand (U.S., Europe, Asia markets), geopolitical normalization, and North American customer adoption post-WQA certification.

Input costs (amines, petrochemicals, resins raw materials) hardened sharply due to geopolitical crisis (crude ₹100+/barrel). Company has initiated price increases across all customer segments but experiencing time lag in realization. Q1 impact: FX headwind ~3-4%, input cost lag accounting for the remaining margin compression. Crude has softened to ₹80/barrel but management cautions 'extremely uncertain, fluid, fluctuating' situation.

Treatment solutions segment reported EBIT loss of ₹17 Cr on ₹210 Cr revenue (negative 8.1% margin). Prior FY21-22 achieved 11-12% margins. Management blames legacy projects but also acknowledges this is inherently a 'lower-margin segment compared to specialty chemicals, products, or services'. Strategy to improve involves selectivity on new projects (e.g., Hyundai, Oman concession) and pivot to advanced/emerging solutions (semiconductors, green hydrogen, resource recovery), but execution track record unproven and these markets nascent.

Consumer products (Zero B brand) delivered ₹112 Cr revenue (+33% YoY growth, fastest segment growth) but still loss-making at ₹34 lakhs (vs ₹45 lakhs prior year). Management target is breakeven in FY27. At ₹112 Cr revenue, even slim 2-3% margin requires significant discipline. Growth is broad-based (filters, purifiers, lab water, softeners, OTGs, heat pumps) across 700+ cities, 2,000+ engineers, expansion into Nepal. However, high capex, distribution overhead, and brand-building costs may make profitability target difficult to achieve.

Hyundai contract (₹400+ Cr solution supply, announced post-quarter) involves supply chain through Iraq, which transits Strait of Hormuz. Contractual terms are FOB Mumbai (company liability ends at Mumbai port), but geopolitical escalation (Iran tensions, Middle East conflict) could disrupt demand realization or extend project timeline. Management acknowledges this but notes contract is with EPC, not end customer directly.